SCHEDULE: Chemomab Shareholders Back Scipher Merger

Chemomab Therapeutics Ltd. shareholders, including HBM Healthcare Investments, have entered into a support agreement to vote in favor of the proposed merger with Scipher Medicine Corporation.

Summary

• This document details a Shareholder Support Agreement between Scipher Medicine Corporation and shareholders of Chemomab Therapeutics Ltd.
• The agreement obligates the shareholders to vote in favor of the merger between Chemomab and Scipher, and against any competing proposals.
• The merger involves Chemomab redomiciling to the U.S. and Scipher becoming a subsidiary, with the combined entity expected to list on Nasdaq under the ticker 'SCIP'.
• Shareholders are restricted from transferring their shares or entering into conflicting agreements.
• The agreement also outlines provisions for pre-funded warrants and potential future milestone payments related to Chemomab's legacy asset, nebokitug.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, as it indicates strong shareholder support for a significant corporate transaction, which is essential for deal completion.

Positives

• Shareholder support secured for the proposed merger, indicating a clear path forward for the transaction.
• HBM Healthcare Investments, a significant shareholder, has committed to voting in favor of the merger.
• The agreement ensures that shareholders will vote against competing acquisition proposals, protecting the merger's integrity.
• Provisions for contingent value rights (CVRs) offer potential upside for shareholders based on future milestones for nebokitug.

Negatives

• The agreement imposes significant restrictions on shareholders' ability to transfer shares or engage in other transactions.
• The exercise of pre-funded warrants is subject to beneficial ownership limitations, potentially impacting the full exercise of rights.
• The success of CVRs is contingent on future regulatory approvals and clinical trial progress, introducing uncertainty.

Risks

• The merger could be delayed or terminated if certain conditions are not met by the 'End Date'.
• Competing acquisition proposals could emerge, although shareholders are obligated to vote against them.
• The effectiveness of the increase in the beneficial ownership limitation for pre-funded warrants is subject to a 61-day waiting period.
• The enforceability of the agreement may be subject to bankruptcy, insolvency, and equitable remedies.

Future Outlook

The merger is expected to be completed in the fourth calendar quarter of 2026. The combined company is expected to be listed on the Nasdaq Capital Market under the ticker symbol 'SCIP'. Holders of Chemomab ADSs and vested options will receive contingent value rights (CVRs) for potential milestone payments related to nebokitug.

Industry Context

StockSavvy.ai notes that this shareholder support agreement is a critical step in the proposed merger between Chemomab Therapeutics and Scipher Medicine. Securing shareholder backing, particularly from significant investors like HBM Healthcare Investments, is crucial for the successful completion of such M&A transactions in the biotechnology sector, which often involves complex regulatory and shareholder approval processes.

Stakeholder Impact

• Shareholders: Will vote on the merger and may receive CVRs for future milestone payments. Their ability to transfer shares is restricted during the agreement term.
• Creditors: The merger and potential future milestones could impact the financial standing and obligations of the combined entity.
• Employees: The merger may lead to changes in employment structure and roles within the combined company.

Next Steps

• Shareholders to vote in favor of the Merger Agreement and Contemplated Transactions.
• Shareholders to vote against any Acquisition Proposal or Acquisition Inquiry relating to Chemomab.
• HBM Healthcare Investments to exercise its Pre-Funded Warrants in full after September 7, 2026, subject to limitations.
• The merger is expected to close in the fourth calendar quarter of 2026.

Key Dates

Recommendation

The filing primarily concerns a shareholder support agreement for a merger, not the company's operational or financial performance. While it indicates progress towards the merger, it does not provide new information to warrant a change in investment strategy beyond holding existing positions pending further details on the combined entity's prospects.

Keywords

Shareholder Support Agreement, Merger, Chemomab Therapeutics, Scipher Medicine Corporation, Acquisition, Voting Agreement, Pre-funded Warrants, CVR